[Efficacy of a multidisciplinary team for preventing hospital-acquired invasive aspergillosis: five years' experience].
Invasive hospital-acquired aspergillosis (IA) is responsible for lethal outbreaks. In 2002, an interdisciplinary team was created in the teaching hospital of Rouen in order to organize the surveillance of construction sites by the implementation of environmental measures of prevention. The aim of our study was to estimate the efficiency of these measures using an indirect indicator, reflecting the incidence of the cases of invasive nosocomial aspergillosis (AI): the consumption of antifungals. From the nominative prescriptions established, we studied the medical files about 210 patients to track down the number of IA cases in intensive care unit (ICUI) and in pediatric hematology-oncology units between 2002 and 2006. The incidence of the cases was put in parallel with the various periods of level 5-risk works during these five years. The relative risk of appearance of the disease was calculated. In pediatric haematology-oncology unit, 35 cases were diagnosed on 99 medical files which have been studied and in ICU 19 cases were classified on 93 studied files. The follow-up of the incidence in both units stake in parallel with the periods of level 5-risk works does not show increase of the number of cases. The calculated relative risk indicates the same result: the level 5-risk works are not a factor facilitating the appearance of invasive aspergillosis cases. This study shows the importance of the environmental measures of prevention during the periods of works within services for risk. The coordination of the actors within an interdisciplinary cell seems thus essential for the prevention of AIN.
Etancelin
P
P
Laboratoire d'hygiène hospitalière, institut de biologie clinique, CHU de Rouen, 1, rue de Germont, 76031 Rouen, France.
Silly
S
S
Merle
V
V
Bonmarchand
G
G
Richard
J-C
JC
Vannier
J-P
JP
Nouvellon
M
M
D016902:Air Pollution, Indoor / Q000517:prevention & control*; D000935:Antifungal Agents / Q000627:therapeutic use; D001228:Aspergillosis / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control* / Q000635:transmission; D002648:Child; D003428:Cross Infection / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control* / Q000635:transmission; D004203:Disinfection / Q000379:methods*; D011307:Drug Prescriptions / Q000706:statistics & numerical data; D004363:Drug Utilization / Q000706:statistics & numerical data; D004780:Environment, Controlled; D004781:Environmental Exposure / Q000517:prevention & control*; D005374:Filtration / Q000295:instrumentation; D005602:France / Q000453:epidemiology; D006405:Hematology; D006748:Hospital Departments / Q000706:statistics & numerical data; D006749:Hospital Design and Construction / Q000592:standards; D006785:Hospitals, University / Q000458:organization & administration; D006801:Humans; D015994:Incidence; D007362:Intensive Care Units / Q000706:statistics & numerical data; D033183:Interdisciplinary Communication; D008495:Medical Oncology; D008499:Medical Records; D008875:Middle Aged; D010372:Pediatrics; D015397:Program Evaluation; D012189:Retrospective Studies; D013172:Spores, Fungal
D000935:Antifungal Agents